CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
SparingVision is developing a gene therapy called RdCVF to treat retinitis pigmentosa, a rare genetic eye disease causing blindness. This innovative treatment aims to halt vision loss by targeting the neurotrophic factor RdCVF, potentially benefiting millions of patients with various genetic forms of the disease.
Many believe that corrective ophthalmology gene therapy is the future for rare diseases such as retinitis pigmentosa (RP), a rare, inherited retinal disorders characterized by diffuse progressive dysfunction of primarily rod photoreceptors, with subsequent degeneration of cone photoreceptors.
This degenerative disease causes blindness to young people and adults.
But with this kind of therapy only treating 1 out of 65 mutations of the pathology, it means a small group of patents can be targeted.S…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
